	US 12,258,401 B2
	Anti-CD47 combination therapy
Sarah Lee Pogue, Redwood City, CA (US); David Scofield Wilson, Jr., Redwood City, CA (US); and Tetsuya Taura, Redwood City, CA (US)
Assigned to TEVA PHARMACEUTICALS AUSTRALIA PTY LTD, New South Wales (AU)
Filed by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD, New South Wales (AU)
Filed on Apr. 29, 2022, as Appl. No. 17/733,378.
Application 17/733,378 is a continuation of application No. 16/317,077, granted, now 11,618,784, previously published as PCT/AU2017/000150, filed on Jul. 19, 2017.
Claims priority of provisional application 62/363,982, filed on Jul. 19, 2016.
Prior Publication US 2022/0259311 A1, Aug. 18, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 38/21 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2803 (2013.01) [A61K 38/212 (2013.01); A61P 35/00 (2018.01); C07K 16/2896 (2013.01)]

21 Claims

1. A composition comprising, in admixture, (i) a polypeptide construct comprising an attenuated Type I interferon α2b (IFNα2b) linked to an antibody which binds to a cell surface-associated antigen expressed on a tumour cell and which comprises a functional Fc region and (ii) a CD47 antagonist which inhibits the interaction of CD47 with the SIRPα receptor, wherein the CD47 antagonist is an anti-CD47 antibody, an anti-SIRPα antibody, or the extracellular domain of SIRPα.